- Home
- OM vs ELEV Comparison
OM vs ELEV Comparison
Compare OM & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OM
- ELEV
- Stock Information
- Founded
- OM 2003
- ELEV 2019
- Country
- OM United States
- ELEV United States
- Employees
- OM N/A
- ELEV N/A
- Industry
- OM Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- OM Health Care
- ELEV Health Care
- Exchange
- OM Nasdaq
- ELEV Nasdaq
- Market Cap
- OM 44.0M
- ELEV 37.6M
- IPO Year
- OM 2020
- ELEV 2021
- Fundamental
- Price
- OM $0.86
- ELEV $0.66
- Analyst Decision
- OM Strong Buy
- ELEV Buy
- Analyst Count
- OM 3
- ELEV 6
- Target Price
- OM $4.00
- ELEV $7.20
- AVG Volume (30 Days)
- OM 1.5M
- ELEV 4.3M
- Earning Date
- OM 02-19-2025
- ELEV 03-05-2025
- Dividend Yield
- OM N/A
- ELEV N/A
- EPS Growth
- OM N/A
- ELEV N/A
- EPS
- OM N/A
- ELEV N/A
- Revenue
- OM $114,729,000.00
- ELEV N/A
- Revenue This Year
- OM N/A
- ELEV N/A
- Revenue Next Year
- OM $10.49
- ELEV N/A
- P/E Ratio
- OM N/A
- ELEV N/A
- Revenue Growth
- OM N/A
- ELEV N/A
- 52 Week Low
- OM $0.44
- ELEV $0.50
- 52 Week High
- OM $5.22
- ELEV $5.83
- Technical
- Relative Strength Index (RSI)
- OM 43.99
- ELEV 48.99
- Support Level
- OM $0.71
- ELEV $0.65
- Resistance Level
- OM $0.84
- ELEV $0.98
- Average True Range (ATR)
- OM 0.17
- ELEV 0.12
- MACD
- OM -0.03
- ELEV -0.01
- Stochastic Oscillator
- OM 15.74
- ELEV 18.38
About OM Outset Medical Inc.
Outset Medical Inc is a medical technology company. It has developed a machine, Tablo, which reduces the cost and complexity of dialysis. Tablo provides Renal Replacement Therapy in Hospitals, Chronic Care in Dialysis Clinics and Home Dialysis.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.